Published 5 days ago • loading... • Updated 5 days ago

Revalesio Announces Publication of RESCUE Phase 2 Trial Results Evaluating RNS60 as an Adjunctive Therapy for Acute Ischemic Stroke in the Journal Stroke

Trial met primary endpoints of similar rates of serious adverse events (SAEs) and fewer deaths observed with RNS60 versus placebo

+2 Reposted by 2 other sources

Trial met primary endpoints of similar rates of serious adverse events (SAEs) and fewer deaths observed with RNS60 versus placebo

5 days ago

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Total News Sources3

Leaning Left1Leaning Right0Center0Last Updated4 days agoBias Distribution

100% Left

100% Left

Untracked bias

To view factuality data please Upgrade to Premium

To view ownership data please Upgrade to Vantage

Antelope Valley Press broke the news in 5 days ago on Monday, July 21, 2025.

Sources are mostly out of (0)